Posted by Michael Wonder on 30 May 2019
Janssen announces Health Canada approval of Tremfya One-Press (guselkumab) - a patient-controlled injector for adults with moderate-to-severe plaque psoriasis
29 May 2019 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that Health Canada has approved Tremfya One-Press, a single-dose, patient-controlled injector for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
In 2017, Tremfya (guselkumab) was the first biologic therapy approved by Health Canada that selectively blocks interleukin-23 (IL-23), an inflammatory protein which is present at increased levels in people with plaque psoriasis. Tremfya One-Press, the only anti-IL-23 with a novel patient-controlled self-injection device, is now available in Canada.
The efficacy and safety of Tremfya administered using a novel patient-controlled injector (One-Press) in patients with moderate-to-severe plaque psoriasis was also evaluated in the ORION study.
